( BW)(NV-ARTEC)(ATKJ) ArTec, Inc., Of Reno, Nevada Announces Completing Its Patent Goals and Has Received the Final Patents from Canada and Western Europe That Were Pending
Pending
Business Editors
RENO, Nev.--(BUSINESS WIRE)--Sept. 27, 2004--ArTec, Inc., (Pink
Sheets: ATKJ) A Pharmaceutical Company announces completing its patent
goals and receiving the final patents from Canada and Western Europe.
On August 13, 2003, the Western European Patent consisting of United
Kingdom, France, Spain, Germany and Italy was issued. On May 11, 2004,
the patent from Canada was issued. The goals accomplished consist of
five final Patents that ArTec, Inc. will utilize:
1. Canada patent issued May 11, 2004, registration number
2,293,821.
2. Western Europe patent issued August 13, 2003, registration
number 0,991,773.
3. United States patent issued August 14, 2001, registration
number 6,274,356.
4. South Korea patent issued October 29, 1998, registration number
173362.
5. Japan patent issued June 12, 1998, registration number
2,790,447.
Dr. Tai Ho Chung, M.D. Ph.D., Principal Partner and Scientific
Advisor for ArTec, Inc. denotes "that having acquired, all five
patents now allows ArTec, Inc. to focus on US FDA submission."
Furthermore, he is encouraged by the fact that research is complete
(Finished Product) and there have been no adverse side effects in
human and mice studies using Tubercin on CANCER. Upon raising funds,
ArTec, Inc. will move quickly into US FDA submission.
What is Tubercin?
The United States Patent issued August 14, 2001, states in the
abstract summary the following:
"A carbohydrate complex, which is a mixture of low
molecular-weight polysaccharides of an arabinomannan structure
extracted from Mycobacterium tuberculosis, is highly effective in
treating various cancer patients without incurring any adverse side
effects." For further information, the US Patent and Trademark
Offices's Official web site can be retrieved from ArTec, Inc.'s web
site at www.artec-inc.net.
Forward-looking statements in this press release, the company
cautions the investors, involve risks and uncertainties pursuant to
the "Safe Harbor" provisions of the Private Securities Litigation
Reform Act of 1995. In addition, the company cautions investors that
it undertakes no obligations or responsibilities to publicly update
these forward-looking statements to reflect Company's expectations
with regard to these forward-looking statements or the occurrence of
unanticipated events.
ArTec, Inc. A Pharmaceutical Company whose goal is to improve the
quality of life!
--30--TM1/na*
CONTACT: ArTec, Inc.
Gerry Knight, 800-388-8875
gknight@artec-inc.net
www.artec-inc.net
KEYWORD: NEVADA ITALY SPAIN GERMANY FRANCE UNITED KINGDOM
INTERNATIONAL CANADA EUROPE
INDUSTRY KEYWORD: PHARMACEUTICAL PRODUCT
SOURCE: ArTec, Inc.
